Sugi Predict

Sugi Predict / Compounds / SCHEMBL3063248

SCHEMBL3063248

SCHEMBL3063248

CC(CNC(=O)OC(C)(C)C)c1cccc(N)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 2/20 0.44
▸ ADRB2 P07550 2/20 0.43
▸ ADRB1 P08588 2/20 0.43
▸ ADRB3 P13945 2/20 0.43
▸ SYK P43405 1/20 0.41
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ CA2 P00918 3/20 0.40
▸ CA1 P00915 2/20 0.40
▸ PCSK9 Q8NBP7 1/20 0.40
▸ MALT1 Q9UDY8 1/20 0.40
▸ CPN1 P15169 1/20 0.40
▸ CPB2 Q96IY4 1/20 0.40
▸ KDM4A O75164 1/20 0.39
▸ NQO2 P16083 1/20 0.39
▸ SERPINE1 P05121 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ UTS2R Q9UKP6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31156775 1.00 AAK1 (0.44) AAK1ADRB2ADRB1ADRB3SYK
SCHEMBL31156795 1.00 AAK1 (0.44) AAK1ADRB2ADRB1ADRB3SYK
SCHEMBL25811680 1.00 AAK1 (0.44) AAK1ADRB2ADRB1ADRB3SYK
SCHEMBL31156788 1.00 AAK1 (0.44) AAK1ADRB2ADRB1ADRB3SYK
SCHEMBL25811681 1.00 AAK1 (0.44) AAK1ADRB2ADRB1ADRB3SYK
SCHEMBL12321338 0.88 BCAT2 (0.43) AAK1ADRB2ADRB1ADRB3SYK
SCHEMBL3051040 0.85 SYK (0.45) AAK1ADRB2ADRB1ADRB3SYK
SCHEMBL16204368 0.84 CTSL (0.47) ADRB2ADRB1ADRB3SYKCTSS
SCHEMBL6028426 0.84 AAK1 (0.49) AAK1SYKCTSSCTSKPCSK9
SCHEMBL7668092 0.84 AAK1 (0.41) AAK1SYKCTSSCTSKCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262795-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 BIOMEA FUSION, INC. 2024-08-08 — — US disclosed
EP-4370506-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 Biomea Fusion, Inc. (US) 2024-05-22 — — EP disclosed
US-11945785-B2 Pyrazine compounds as inhibitors of FLT3 BIOMEA FUSION, INC. (US) 2024-04-02 — — US disclosed
US-20230339867-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 BIOMEA FUSION, INC. 2023-10-26 — — US disclosed
US-20230339867-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 BIOMEA FUSION, INC. 2023-10-26 — — US disclosed
WO-2023129667-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 BIOMEA FUSION, INC. (US) 2023-07-06 — — WO disclosed
WO-2023129667-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 BIOMEA FUSION, INC. (US) 2023-07-06 — — WO disclosed
US-7834049-B2 Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-11-16 — — US disclosed
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR WAKABAYASHI TOSHIAKI 2010-10-21 — — US disclosed
EP-1904494-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS ELI LILLY AND COMPANY (US) 2008-04-02 — — EP disclosed
EP-1243583-B1 HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS EISAI CO LTD (JP) 2005-09-28 — — EP disclosed
US-20050176712-A1 Integrin expression inhibitor EISAI CO., LTD. 2005-08-11 — — US disclosed
EP-0798292-B1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) 2004-11-03 — — EP disclosed
US-6787534-B2 SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS EISAI CO., LTD. (JP) 2004-09-07 — — US disclosed
US-20040018192-A1 Integrin expression inhibitors EISAI CO., LTD. (JP) 2004-01-29 — — US disclosed
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-07-31 — — US disclosed
US-6534546-B1 Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-18 — — US disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
EP-1243583-A1 HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS Eisai Co., Ltd. (JP) 2002-09-25 — — EP disclosed
EP-0798292-A1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY Chugai Seiyaku Kabushiki Kaisha (JP) 1997-10-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176712-A1 Integrin expression inhibitor ITGB5, ITGB1, ITGB2 AAK1 4043/4885ADRB2 1001/4885ADRB1 577/4885
US-20240262795-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 FLT3, MCL1, CSF3R AAK1 3206/4885ADRB2 4828/4885ADRB1 4774/4885
US-11945785-B2 Pyrazine compounds as inhibitors of FLT3 FLT3, MCL1, JAK2 AAK1 3352/4885ADRB2 4760/4885ADRB1 4613/4885
US-20230339867-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 FLT3, MCL1, CSF3R AAK1 3206/4885ADRB2 4828/4885ADRB1 4774/4885
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR ITGB5, ITGB1, ITGB2 AAK1 4043/4885ADRB2 1001/4885ADRB1 577/4885
US-20040018192-A1 Integrin expression inhibitors ITGB1, ITGB4, ITGB5 AAK1 3895/4885ADRB2 1094/4885ADRB1 559/4885
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds SLC5A2, SLC5A1, CBR3 AAK1 4605/4885ADRB2 1410/4885ADRB1 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.